Thomas J. Polascik, MD, FACS, presented “Integration of Germline Testing in Prostate Cancer Screening” for the Grand Rounds in Urology audience in November, 2019.
How to cite: Polascik, Thomas J. “Integration of Germline Testing in Prostate Cancer Screening” November, 2019. Accessed Oct 2022. https://dev.grandroundsinurology.com/integration-of-germline-testing-in-prostate-cancer-screening/
Integration of Germline Testing in Prostate Cancer Screening – Summary:
Thomas J. Polascik, MD, FACS, surveys the current status of germline testing for prostate cancer in screening populations, and explains how his institution, Duke University, has been advancing research in this area. He discusses current studies measuring the ability of germline testing to predict outcomes, highlights the Duke algorithm for when and whom to test, and describes challenges for integrating germline testing into the current model of prostate cancer screening.
This educational activity is based on a series of lectures on genetic testing for prostate cancer from the 2019 Philadelphia Prostate Cancer Consensus Conference. Further activities from this conference include:
Germline Predisposition for Prostate Cancer Among African American and Other Minorities: What Do We Know?
Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness
Prostate Cancer Screening & Genetic Testing: The NCCN Perspective
Current NCCN Recommendations for Prostate Cancer Genetic Testing
The Expanding World of Germline Testing for Prostate Cancer: Genetic Counseling Perspective
The Expanding World of Germline Testing for Prostate Cancer: A Clinical Trials Perspective
Current Prostate Cancer Genetic Testing Capabilities and Considerations
A Urologist’s Perspective on Germline Testing